profit from every $100 of sales.
$0$100
Inventiva
$3.84+1.05% today
-4.2% in 1 year
1-year low $2.871-year high $7.15
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Inventiva sold, what it kept, and what it did with the cash.
Sales went from €12.2 million in 2022 to €4.48 million in 2025, with -€354 million of profit last year.
SalesProfit
Inventiva vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Inventiva | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Inventiva's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 12 | 17 | 9 | 4 | |
| – | – | – | – | |
| -57 | -103 | -94 | -133 | |
| -52 | -102 | -167 | -317 | |
| -54 | -110 | -184 | -354 | |
| -1.31 | -2.43 | -3.08 | -1.90 | |
| – | – | – | – | |
| -466.8% | -587.4% | -1,021.8% | -2,964.2% | |
| -445.6% | -631.8% | -2,002.7% | -7,899.6% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 116 | 70 | 119 | 250 |
| Cash | 87 | 27 | 97 | 99 |
| Total debt | 35 | 37 | 54 | 60 |
| Total liabilities | 71 | 102 | 226 | 278 |
| 45 | -32 | -107 | -29 | |
| 41 | 45 | 60 | 186 | |
| -52.9% | -1,514.6% | – | -808.1% | |
| -119.3% | 344.7% | 172.7% | 1,241.6% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -45 | -82 | -86 | -105 | |
| 1 | 1 | 0 | 0 | |
| -45 | -82 | -86 | -105 | |
| Dividends paid | – | 0 | 0 | 0 |
| – | – | – | – | |
| 2 | 4 | 4 | 27 |
Valuation
- –
- –
- –
- -101.6×
- 182.4×
- –
- –
- -12.9%
- -43.3%
- 0.0%
Profitability
- 35.1%
- -2,964.2%
- -7,899.6%
- -2,976.0%
- -66.2%
- -582.0%
- 1,870.4%
- -141.9%
- -79.1%
- 1,931.5%
Growth
- −28.3%
- –
- −17.3%
- –
- +47.8%
Financial health
- -0.1×
- -2.10
- 24.0%
- -4.1×
- 3.16
- 3.16
- 0.02
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 948
Bottom 4%of 868
Bottom 8%of 985
What analysts expect
- Average price target
- $15.80
- Range
- $12.00 – $24.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 30, 2026 | -1.07 | -0.23 | −365.2% |
| Sep 25, 2025 | -1.89 | -0.41 | −361.7% |
| May 23, 2025 | -2.69 | -0.47 | −472.9% |
| Sep 25, 2024 | -1.01 | -0.56 | −81.1% |
| Mar 27, 2024 | -1.25 | -0.40 | −211.7% |
| Sep 28, 2023 | -1.43 | -1.27 | −13.1% |
| Mar 29, 2023 | -0.64 | -0.57 | −11.9% |
| Sep 19, 2022 | -0.75 | -0.90 | +16.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
17No pass
Benjamin Graham
43No pass
Philip Fisher
30No pass
Peter Lynch
–Not enough data
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
23No pass
Questions about Inventiva
Is Inventiva a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Inventiva AI analysis
What does Inventiva do?
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. It is in Biotechnology.
Does Inventiva pay a dividend?
No. Inventiva does not pay a dividend at the moment.
Is Inventiva stock halal?
Yes. Inventiva passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has Inventiva stock done over the past year?
Down 4.2% over the past twelve months, to $3.84. It traded between $2.87 and $7.15 and is 46.3% below its high.
Who are Inventiva's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Inventiva's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.